Clinical Trials Logo

Fatigue clinical trials

View clinical trials related to Fatigue.

Filter by:

NCT ID: NCT05000918 Completed - Healthy Clinical Trials

Functional Food Application of Okara Protein Hydrolysate (OPH)- for Anti-exercise-fatigue

Start date: July 17, 2020
Phase: N/A
Study type: Interventional

The aim of this study is to investigate the anti-exercise-fatigue effects of okara protein hydrolysate (OPH) in men

NCT ID: NCT04995614 Completed - Bone Metastases Clinical Trials

Health-related Quality of Life, Psychological Distress and Fatigue in Metastatic CRPC Patients Treated With Radium-223

Start date: April 1, 2017
Phase:
Study type: Observational

The aim of the current prospective multicenter study is to evaluate cancer-specific and bone metastases related HR-QoL, psychological distress and fatigue in mCRPC patients before, during and after treatment with radium-223 in daily practice. Furthermore, the investigators aim to determine patient groups with identical health-related quality of life patterns over time, in order to identify variables related to health-related quality of life deterioration during the course of treatment, as patients with health-related quality of life deterioration may need specific attention to preserve health-related quality of life.

NCT ID: NCT04994600 Completed - Alarm Fatigue Clinical Trials

Design and Validation of a German Language Questionnaire for Measuring Alarm Fatigue in Intensive Care Units

alarmZen1
Start date: March 19, 2021
Phase:
Study type: Observational

False-positive and non-actionable alarms can lead to staff desensitization ("alarm fatigue") and thus patient endangerment. With this study the investigators create a basic tool to survey alarm fatigue of intensive care staff: the first German language alarm fatigue questionnaire.

NCT ID: NCT04988880 Active, not recruiting - Multiple Sclerosis Clinical Trials

Territorial Implementation and Evaluation of a Multiple Sclerosis Expert Patient Program

Start date: November 1, 2021
Phase: N/A
Study type: Interventional

Introduction: Multiple sclerosis (MS) affects about 50,000 people in Spain, so it is essential to implement health interventions that meet their needs and demands. Expert patient programs facilitate health-related empowerment through peer learning. From a study of focus groups that identified the characteristics and contents of an expert patient program for MS and the ongoing pilot tests, the need for implementation in the different reference units of Catalonia is established. Hypothesis: The territorial implementation in Catalonia of a Catalonia® Expert Patient Program for people with MS (PPEC-EM) based on peer learning will improve the quality of life, knowledge and self-management related to the health process of the participants. Objective: To deploy and evaluate the territorial implementation of a PPEC-EM based on peer learning regarding the quality of life, knowledge and self-management related to the health process of the participants. Methodology: Pre-post intervention multicenter clinical study. This study will begin after the approval of the respective Ethics Committees. The deployment will consist of 12 groups of patients (2 per unit): 6 groups with people with recurrent MS and 6 groups with people with progressive MS. A patient with MS previously trained by a team of health professionals will lead 9 educational group sessions (1 weekly session for 9 weeks) with 12 people with the same disease in order to improve the impact and self-management according to the health process. The main variable is the improvement of the quality of life and the secondary ones are the emotional impact, activation of the person, knowledge on the MS, fatigue, habits and lifestyles, use of the sanitary services and program-related experience of participants. All variables will be measured before and after the intervention and after 6 and 12 months. A pre-post comparability analysis will be developed in relation to the variables studied.

NCT ID: NCT04988126 Recruiting - Pain Clinical Trials

Pain, Fatigue and Life Quality in COVID-19 Patients

Start date: February 1, 2021
Phase:
Study type: Observational

The aim in this study is to evaluate pain, fatigue and quality of life in patients with Covid-19 pneumonia in long-term follow-up and to investigate their relationship with pneumonia severity, age, presence of comorbidity and depression level.

NCT ID: NCT04984226 Recruiting - Diabetes Clinical Trials

Sodium Bicarbonate and Mitochondrial Energetics in Persons With CKD

Senergy-CKD
Start date: September 8, 2023
Phase: Phase 2
Study type: Interventional

Skeletal muscle metabolic health is critical for mobility and an underrecognized target of metabolic acidosis in chronic kidney disease. Impaired muscle mitochondrial metabolism underlies poor physical endurance increasing the risk of mobility disability. The proposed project will use precise in vivo tools to study the pathophysiology of poor physical endurance in a clinical trial treating metabolic acidosis among persons living with chronic kidney disease.

NCT ID: NCT04983342 Completed - Fatigue Clinical Trials

Apollo Device for Metastatic Breast Cancer (MBC)

Start date: February 1, 2021
Phase: N/A
Study type: Interventional

This is a single-arm, open label pilot intervention study with outcomes measured by electronic survey and chart review evaluating a wearable device called Apollo, which is similar to a FitBit but emits vibrations. Our primary objective is to assess whether or not Apollo can help with symptoms of fatigue and pain in patients with Metastatic Breast Cancer (MBC).

NCT ID: NCT04980573 Completed - Covid19 Clinical Trials

Essential Oils and Post COVID-19 Fatigue

Start date: August 5, 2021
Phase: N/A
Study type: Interventional

The purpose of this study is to assess the efficacy of plant based aromas on energy levels among otherwise healthy female survivors of COVID-19.

NCT ID: NCT04975802 Completed - Cognition Clinical Trials

Effect of Coffeeberry on Mood and Cognitive Performance

Start date: July 5, 2021
Phase: N/A
Study type: Interventional

The primary aim of this randomised, double-blind, placebo-controlled, cross-over study is to assess the short-term cognitive effects of two beverages containing 100 and 300 mg coffeeberry extract (obtained from the fruit of the coffee plant (Coffea arabica) compared to a placebo beverage. The trial will utilise the COMPASS cognitive assessment system and cognitive demand battery (CDB) and mood visual analogue scales (VAS) with assessments taking place at baseline, 60- and 120-minutes post treatment, on four separate testing days separated by 7 days. A treatment containing 75 mg caffeine will be used as a positive control to document participants' responsiveness to an established psychostimulant.

NCT ID: NCT04975087 Not yet recruiting - Clinical trials for Primary Sjögren's Syndrome

The Profile of Fatigue and Discomfort - Sicca Symptoms Inventory

Start date: October 15, 2021
Phase:
Study type: Observational

Primary Sjögren's syndrome (pSS) is a chronic, systemic autoimmune disease characterized by disorders of the lacrimal and salivary glands. The disease can be seen in systemic involvement by affecting any organ. It may result in skin, lung and kidney involvement as well as symptoms such as vasculitis and neuropathy. Patients with PSS often report fatigue as an important symptom to manage. Fatigue, defined as an overwhelming feeling of fatigue, lack of energy, and exhaustion, is associated with poor health and functional impairment. Fatigue is a common symptom of pSS. This symptom is the most important cause of loss of function in patients. It is thought that as a result of fatigue in pSS, decrease in mental health related to physical activity level and quality of life in patients, sleep problems, depression and loss of ability to work. Several mechanisms have been proposed to explain the occurrence of fatigue among sjogren patients, but its underlying physiological basis has not been adequately defined. Therefore, it is a complex, multifaceted and poorly understood symptom. In population-based studies, approximately 20% of healthy adults report experiencing fatigue, and this rate rises to 60%-70% among patients with autoimmune disorders. Fatigue is the most common non-exocrine symptom in pSS, and the prevalence of fatigue disability among patients with pSS has been reported to be approximately 70%.